Dr. Sammons is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
450 Brookline Ave
Boston, MA 02215Phone+1 617-632-3800Fax+1 617-632-1930
Summary
- Sarah Sammons, MD, is an Oncologist based in Boston, MA, with a subspecialty in Breast Cancer. She graduated from the Sidney Kimmel Medical College at Thomas Jefferson University in 2012. Dr. Sammons has contributed to the medical field with multiple publications, predominantly in the field of cancers and their treatment options, some of which have been extensively cited. Furthermore, she has played various roles such as Sponsor-Investigator, Principal Investigator, and Contact in several clinical trials targeting different aspects of breast cancer, including brain metastases and hormone receptor positive breast cancer.
Education & Training
Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 2012
Certifications & Licensure
MA State Medical License 2022 - 2025
NC State Medical License 2018 - 2023- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib Start of enrollment: 2023 Mar 23
Roles: Contact
- Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation Start of enrollment: 2023 Oct 31
Roles: Contact
- DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs Start of enrollment: 2023 Dec 26
Roles: Sponsor-Investigator, Principal Investigator, Contact
Publications & Presentations
PubMed
- 2 citationsImlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Grow...Komal L Jhaveri, Elgene Lim, Rinath Jeselsohn, Cynthia X Ma, Erika P Hamilton
Journal of Clinical Oncology. 2024-12-10 - Genomic landscape of malignant phyllodes tumors reveals multiple targetable opportunities.Laura H Rosenberger, Richard F Riedel, Emilia J Diego, Amanda L Nash, Juneko E Grilley-Olson
The Oncologist. 2024-12-06 - Genomic Landscape of Malignant Phyllodes Tumors Identifies Subsets for Targeted Therapy.Rani Bansal, Tolulope Adeyelu, Andrew Elliott, Antoinette R Tan, Jennifer R Ribeiro
JCO Precision Oncology. 2024-12-01
Press Mentions
Systemic Therapy Shows Increasing Promise for CNS Metastases in Breast CancerAugust 5th, 2023- CDK4/6 Inhibitor Selection and Sequencing Continue to Evolve in HR+ Breast CancerSeptember 9th, 2023
- New Approaches in the Treatment of HR+ Metastatic Breast CancerJuly 11th, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
